VVOS
Vivos Therapeutics, Inc.
Price Chart
Latest Quote
$0.61
-0.03 (-3.94%)
Current Price
| Previous Close | $0.64 |
| Open | $0.67 |
| Day High | $0.67 |
| Day Low | $0.55 |
| Volume | 416,263 |
Stock Information
| Shares Outstanding | 13.89M |
| Total Debt | $12.27M |
| Cash Equivalents | $2.11M |
| Revenue | $19.57M |
| Net Income | $-24.99M |
| Sector | Healthcare |
| Industry | Medical Devices |
| Market Cap | $7.95M |
| EPS (TTM) | $-2.14 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $17.98M |
| Sales | $19.57M |
| Income | $-24.99M |
| Book/sh | $0.31 |
| Cash/sh | $0.15 |
| Employees | 270 |
Financial Ratios
| Quick Ratio | 0.22 |
| Current Ratio | 0.27 |
Returns & Margins
| ROA | -77.74% |
| ROE | -1599.81% |
| Gross Margin | 61.79% |
| Operating Margin | -128.67% |
| Profit Margin | -127.70% |
Ownership
| Insider Ownership | 25.72% |
| Institutional Ownership | 14.07% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -0.68 |
| P/S | 0.41 |
| P/B | 1.87 |
Analyst Data
| Recommendation | buy |
| Target Price | $2.45 |
Technical Indicators
| SMA20 | $0.66 |
| SMA50 | $0.84 |
| SMA200 | $1.94 |
| RSI | 47.17 |
| ATR | 0.1399 |
| Shares Float | 12.05M |
| Short Float | 7.07% |
| Short Ratio | 4.93 |
| Volatility | 6.08 |
| Rel Volume | 0.07 |
Performance History
| Week | -33.87% |
| Month | -20.11% |
| Quarter | -53.87% |
| 6 Months | -73.88% |
| YTD | -77.39% |
| Year | -74.23% |
| 3 Years | -94.49% |
| 5 Years | -99.55% |
| 10 Years | -99.75% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-12 | $0.57 | 279,400 |
| 2026-06-11 | $0.61 | 426,300 |
| 2026-06-10 | $0.64 | 837,700 |
| 2026-06-09 | $0.70 | 1,322,900 |
| 2026-06-08 | $0.87 | 3,870,300 |
| 2026-06-05 | $0.87 | 70,279,200 |
| 2026-06-04 | $0.69 | 40,500 |
| 2026-06-03 | $0.64 | 147,000 |
| 2026-06-02 | $0.68 | 66,800 |
| 2026-06-01 | $0.69 | 141,100 |
| 2026-05-29 | $0.70 | 57,800 |
| 2026-05-28 | $0.67 | 101,800 |
| 2026-05-27 | $0.66 | 228,100 |
| 2026-05-26 | $0.65 | 127,800 |
| 2026-05-22 | $0.61 | 143,700 |
| 2026-05-21 | $0.58 | 256,400 |
| 2026-05-20 | $0.59 | 278,300 |
| 2026-05-19 | $0.58 | 55,300 |
| 2026-05-18 | $0.60 | 208,300 |
| 2026-05-15 | $0.64 | 138,200 |
| 2026-05-14 | $0.69 | 158,100 |
| 2026-05-13 | $0.72 | 149,300 |
About Vivos Therapeutics, Inc.
Vivos Therapeutics, Inc. operates as a medical technology and healthcare services company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. The company was formerly known as Vivos BioTechnologies, Inc. and changed its name to Vivos Therapeutics, Inc. in March 2018. The company was founded in 2016 and is based in Littleton, Colorado.
đ° Latest News
Vivos Therapeutics Plans to File for Proposed Rights Offering
MT Newswires âĸ 2026-06-11T13:11:26ZSector Update: Healthcare Stocks Higher Late Afternoon
MT Newswires âĸ 2026-06-05T19:49:02ZVivos Therapeutics Inc (VVOS) Q1 2026 Earnings Call Highlights: Revenue Surges Amid Strategic Shifts
GuruFocus.com âĸ 2026-05-29T01:02:00ZPlus Therapeutics (PSTV) Reports Q1 Loss, Tops Revenue Estimates
Zacks âĸ 2026-05-15T21:20:01Z
Vivos Therapeutics Inc (VVOS) Q4 2025 Earnings Call Highlights: Revenue Growth Amid Strategic ...
GuruFocus.com âĸ 2026-04-16T07:01:54ZVivos Therapeutics, Inc. Q4 2025 Earnings Call Summary
Moby âĸ 2026-04-15T12:30:00Z
NRx Pharmaceuticals, Inc. (NRXP) Surpasses Q4 Earnings Estimates
Zacks âĸ 2026-03-23T22:10:02Z
Theravance Biopharma (TBPH) Q4 Earnings and Revenues Lag Estimates
Zacks âĸ 2026-03-19T13:40:01Z
Health Catalyst (HCAT) Lags Q4 Earnings Estimates
Zacks âĸ 2026-03-12T22:05:02Z
Rigel Pharmaceuticals (RIGL) Q4 Earnings Miss Estimates
Zacks âĸ 2026-03-03T22:15:02Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $6,901,000 | $6,012,000 | $5,530,000 | $6,005,000 |
| Cost Of Revenue | $6,901,000 | $6,012,000 | $5,530,000 | $6,005,000 |
| Total Revenue | $17,443,000 | $15,031,000 | $13,801,000 | $16,024,000 |
| Operating Revenue | $17,443,000 | $15,031,000 | $13,801,000 | $16,024,000 |
| Expenses | ||||
| Total Expenses | $37,337,000 | $26,202,000 | $31,097,000 | $41,055,000 |
| Other Income Expense | $-1,336,000 | $35,000 | $3,713,000 | $1,186,000 |
| Other Non Operating Income Expenses | $-1,336,000 | $35,000 | $-65,000 | $-101,000 |
| Operating Expense | $30,436,000 | $20,190,000 | $25,567,000 | $35,050,000 |
| Selling And Marketing Expense | $1,400,000 | $1,731,000 | $2,467,000 | $5,340,000 |
| General And Administrative Expense | $27,727,000 | $17,878,000 | $22,479,000 | $29,041,000 |
| Interest Expense | - | - | - | $0 |
| Net Non Operating Interest Income Expense | - | - | - | $0 |
| Interest Expense Non Operating | - | - | - | $0 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-21,230,000 | $-11,136,000 | $-13,583,000 | $-23,845,000 |
| Normalized Income | $-21,230,000 | $-11,136,000 | $-17,361,000 | $-25,132,000 |
| Net Income From Continuing And Discontinued Operation | $-21,230,000 | $-11,136,000 | $-13,583,000 | $-23,845,000 |
| Total Operating Income As Reported | $-19,894,000 | $-11,171,000 | $-17,296,000 | $-25,031,000 |
| Net Income Common Stockholders | $-21,230,000 | $-11,136,000 | $-13,583,000 | $-23,845,000 |
| Net Income | $-21,230,000 | $-11,136,000 | $-13,583,000 | $-23,845,000 |
| Net Income Including Noncontrolling Interests | $-21,230,000 | $-11,136,000 | $-13,583,000 | $-23,845,000 |
| Net Income Continuous Operations | $-21,230,000 | $-11,136,000 | $-13,583,000 | $-23,845,000 |
| Pretax Income | $-21,230,000 | $-11,136,000 | $-13,583,000 | $-23,845,000 |
| Operating Income | $-19,894,000 | $-11,171,000 | $-17,296,000 | $-25,031,000 |
| Depreciation Amortization Depletion Income Statement | $1,309,000 | $581,000 | $621,000 | $669,000 |
| Depreciation And Amortization In Income Statement | $1,309,000 | $581,000 | $621,000 | $669,000 |
| Gross Profit | $10,542,000 | $9,019,000 | $8,271,000 | $10,019,000 |
| Special Income Charges | - | - | $0 | $1,287,000 |
| Net Interest Income | - | - | - | $0 |
| Interest Income | - | - | - | - |
| Interest Income Non Operating | - | - | - | - |
| Per Share | ||||
| Diluted EPS | $-2.07 | $-2.22 | $-11.14 | $-25.90 |
| Basic EPS | $-2.07 | $-2.22 | $-11.14 | $-25.90 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-18,585,000 | $-10,590,000 | $-20,453,000 | $-25,649,000 |
| Reconciled Depreciation | $1,309,000 | $581,000 | $621,000 | $669,000 |
| EBITDA (Bullshit earnings) | $-18,585,000 | $-10,590,000 | $-16,675,000 | $-24,362,000 |
| EBIT | $-19,894,000 | $-11,171,000 | $-17,296,000 | $-25,031,000 |
| Diluted Average Shares | $10,273,881 | $5,019,886 | $1,219,381 | $920,592 |
| Basic Average Shares | $10,273,881 | $5,019,886 | $1,219,381 | $920,592 |
| Diluted NI Availto Com Stockholders | $-21,230,000 | $-11,136,000 | $-13,583,000 | $-23,845,000 |
| Selling General And Administration | $29,127,000 | $19,609,000 | $24,946,000 | $34,381,000 |
| Other Gand A | $27,727,000 | $17,878,000 | $22,479,000 | $29,041,000 |
| Total Unusual Items | - | - | $3,778,000 | $1,287,000 |
| Total Unusual Items Excluding Goodwill | - | - | $3,778,000 | $1,287,000 |
| Gain On Sale Of Security | - | - | $3,778,000 | - |
| Tax Provision | - | - | - | $0 |
| Other Special Charges | - | - | - | $-1,287,000 |
| Write Off | - | - | - | $0 |
| Otherunder Preferred Stock Dividend | - | - | - | - |
Fetched: 2026-06-11
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-14,107,000 | $4,702,000 | $-2,852,000 | $1,656,000 |
| Total Assets | $25,152,000 | $15,284,000 | $10,730,000 | $13,720,000 |
| Total Non Current Assets | $20,768,000 | $7,811,000 | $8,269,000 | $8,296,000 |
| Other Non Current Assets | $228,000 | $216,000 | $307,000 | $374,000 |
| Goodwill And Other Intangible Assets | $12,617,000 | $3,252,000 | $3,263,000 | $3,145,000 |
| Other Intangible Assets | $4,045,000 | $409,000 | $420,000 | $302,000 |
| Current Assets | $4,384,000 | $7,473,000 | $2,461,000 | $5,424,000 |
| Other Current Assets | $774,000 | $783,000 | $616,000 | $1,448,000 |
| Receivables | $1,581,000 | $430,000 | $202,000 | $457,000 |
| Accounts Receivable | $1,581,000 | $430,000 | $202,000 | $457,000 |
| Allowance For Doubtful Accounts Receivable | $-882,000 | $-390,000 | $-268,000 | $-712,000 |
| Gross Accounts Receivable | $2,463,000 | $820,000 | $470,000 | $1,169,000 |
| Cash Cash Equivalents And Short Term Investments | $2,029,000 | $6,260,000 | $1,643,000 | $3,519,000 |
| Cash And Cash Equivalents | $2,029,000 | $6,260,000 | $1,643,000 | $3,519,000 |
| Non Current Prepaid Assets | - | - | - | $374,000 |
| Non Current Note Receivables | - | - | - | - |
| Prepaid Assets | - | - | - | - |
| Other Receivables | - | - | - | - |
| Notes Receivable | - | - | - | - |
| Debt | ||||
| Net Debt | $6,793,000 | - | - | - |
| Total Debt | $13,502,000 | $1,512,000 | $1,995,000 | $2,413,000 |
| Long Term Debt And Capital Lease Obligation | $4,422,000 | $1,035,000 | $1,521,000 | $1,994,000 |
| Long Term Debt | $469,000 | - | - | - |
| Current Debt And Capital Lease Obligation | $9,080,000 | $477,000 | $474,000 | $419,000 |
| Current Debt | $8,353,000 | - | - | - |
| Other Current Borrowings | $8,353,000 | - | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $26,702,000 | $7,330,000 | $10,319,000 | $8,919,000 |
| Total Non Current Liabilities Net Minority Interest | $8,626,000 | $2,352,000 | $3,030,000 | $2,106,000 |
| Other Non Current Liabilities | $1,300,000 | - | - | - |
| Non Current Deferred Liabilities | $0 | $97,000 | $289,000 | $112,000 |
| Current Liabilities | $18,076,000 | $4,978,000 | $7,289,000 | $6,813,000 |
| Other Current Liabilities | $850,000 | $273,000 | $198,000 | $145,000 |
| Current Deferred Liabilities | $479,000 | $896,000 | $2,138,000 | $2,926,000 |
| Payables And Accrued Expenses | $7,667,000 | $3,332,000 | $4,479,000 | $3,323,000 |
| Interest Payable | $1,952,000 | $0 | - | - |
| Payables | $2,478,000 | $1,579,000 | $2,472,000 | $1,411,000 |
| Total Tax Payable | $799,000 | $481,000 | $327,000 | - |
| Accounts Payable | $1,679,000 | $1,098,000 | $2,145,000 | $1,411,000 |
| Equity | ||||
| Common Stock Equity | $-1,490,000 | $7,954,000 | $411,000 | $4,801,000 |
| Total Equity Gross Minority Interest | $-1,550,000 | $7,954,000 | $411,000 | $4,801,000 |
| Stockholders Equity | $-1,490,000 | $7,954,000 | $411,000 | $4,801,000 |
| Retained Earnings | $-125,357,000 | $-104,187,000 | $-93,051,000 | $-79,468,000 |
| Other | ||||
| Ordinary Shares Number | $9,286,609 | $5,889,520 | $1,833,877 | $920,484 |
| Share Issued | $9,286,609 | $5,889,520 | $1,833,877 | $920,484 |
| Tangible Book Value | $-14,107,000 | $4,702,000 | $-2,852,000 | $1,656,000 |
| Invested Capital | $7,332,000 | $7,954,000 | $411,000 | $4,801,000 |
| Working Capital | $-13,692,000 | $2,495,000 | $-4,828,000 | $-1,389,000 |
| Capital Lease Obligations | $4,680,000 | $1,512,000 | $1,995,000 | $2,413,000 |
| Total Capitalization | $-1,021,000 | $7,954,000 | $411,000 | $4,801,000 |
| Minority Interest | $-60,000 | $0 | - | - |
| Additional Paid In Capital | $123,866,000 | $112,141,000 | $93,462,000 | $84,269,000 |
| Capital Stock | $1,000 | $0 | $0 | $0 |
| Common Stock | $1,000 | $0 | $0 | $0 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Employee Benefits | $2,904,000 | $1,220,000 | $1,220,000 | $0 |
| Non Current Deferred Revenue | $0 | $97,000 | $289,000 | $112,000 |
| Long Term Capital Lease Obligation | $3,953,000 | $1,035,000 | $1,521,000 | $1,994,000 |
| Current Deferred Revenue | $479,000 | $896,000 | $2,138,000 | $2,926,000 |
| Current Capital Lease Obligation | $727,000 | $477,000 | $474,000 | $419,000 |
| Current Accrued Expenses | $5,189,000 | $1,753,000 | $2,007,000 | $1,912,000 |
| Goodwill | $8,572,000 | $2,843,000 | $2,843,000 | $2,843,000 |
| Net PPE | $7,923,000 | $4,343,000 | $4,699,000 | $4,777,000 |
| Accumulated Depreciation | $-2,936,000 | $-2,780,000 | $-2,326,000 | $-1,753,000 |
| Gross PPE | $10,859,000 | $7,123,000 | $7,025,000 | $6,530,000 |
| Leases | $3,197,000 | $2,479,000 | $2,479,000 | $2,479,000 |
| Construction In Progress | $0 | $1,857,000 | $1,435,000 | $948,000 |
| Other Properties | $4,572,000 | $1,438,000 | $1,790,000 | $1,838,000 |
| Machinery Furniture Equipment | $3,090,000 | $1,349,000 | $1,321,000 | $1,265,000 |
| Properties | $0 | $0 | $0 | $0 |
| Dueto Related Parties Current | - | - | - | - |
Fetched: 2026-06-11
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-17,604,000 | $-13,259,000 | $-12,749,000 | $-20,511,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-15,263,000 | $-12,691,000 | $-11,946,000 | $-19,587,000 |
| Cash Flow From Continuing Operating Activities | $-15,263,000 | $-12,691,000 | $-11,946,000 | $-19,587,000 |
| Operating Gains Losses | - | $31,000 | $-3,041,000 | $-518,000 |
| Investing Activities | ||||
| Capital Expenditure | $-2,341,000 | $-568,000 | $-803,000 | $-924,000 |
| Investing Cash Flow | $-7,526,000 | $-568,000 | $-853,000 | $-924,000 |
| Cash Flow From Continuing Investing Activities | $-7,526,000 | $-568,000 | $-853,000 | $-924,000 |
| Net Other Investing Changes | - | - | $-50,000 | - |
| Financing Activities | ||||
| Issuance Of Capital Stock | $5,576,000 | $7,796,000 | $4,000,000 | $0 |
| Financing Cash Flow | $18,558,000 | $17,876,000 | $10,923,000 | $0 |
| Cash Flow From Continuing Financing Activities | $18,558,000 | $17,876,000 | $10,923,000 | $0 |
| Net Other Financing Charges | $-837,000 | $-1,361,000 | $-1,077,000 | - |
| Net Common Stock Issuance | $5,576,000 | $7,796,000 | $4,000,000 | $0 |
| Common Stock Issuance | $5,576,000 | $7,796,000 | $4,000,000 | $0 |
| Repurchase Of Capital Stock | - | - | - | $0 |
| Net Preferred Stock Issuance | - | - | - | $0 |
| Preferred Stock Issuance | - | - | - | - |
| Other | ||||
| Repayment Of Debt | $-28,000 | $0 | - | $0 |
| Issuance Of Debt | $10,673,000 | $0 | - | - |
| Interest Paid Supplemental Data | $0 | $9,000 | $0 | $0 |
| End Cash Position | $2,029,000 | $6,260,000 | $1,643,000 | $3,519,000 |
| Beginning Cash Position | $6,260,000 | $1,643,000 | $3,519,000 | $24,030,000 |
| Changes In Cash | $-4,231,000 | $4,617,000 | $-1,876,000 | $-20,511,000 |
| Proceeds From Stock Option Exercised | $3,174,000 | $11,441,000 | $8,000,000 | - |
| Net Issuance Payments Of Debt | $10,645,000 | $0 | - | $0 |
| Net Long Term Debt Issuance | $10,645,000 | $0 | - | $0 |
| Long Term Debt Payments | $-28,000 | $0 | - | $0 |
| Long Term Debt Issuance | $10,673,000 | $0 | - | - |
| Net Business Purchase And Sale | $-5,185,000 | $0 | - | $0 |
| Purchase Of Business | $-5,185,000 | $0 | - | $0 |
| Net PPE Purchase And Sale | $-2,341,000 | $-568,000 | $-803,000 | $-924,000 |
| Purchase Of PPE | $-2,341,000 | $-568,000 | $-803,000 | $-924,000 |
| Change In Working Capital | $3,997,000 | $-2,940,000 | $2,864,000 | $1,711,000 |
| Change In Other Working Capital | $-514,000 | $-1,434,000 | $-611,000 | $1,154,000 |
| Change In Other Current Liabilities | $538,000 | $-129,000 | $1,152,000 | $151,000 |
| Change In Payables And Accrued Expense | $4,142,000 | $-1,087,000 | $1,156,000 | $-450,000 |
| Change In Accrued Expense | $3,618,000 | $-39,000 | $422,000 | $-941,000 |
| Change In Payable | $524,000 | $-1,048,000 | $734,000 | $491,000 |
| Change In Account Payable | $524,000 | $-1,048,000 | $734,000 | $491,000 |
| Change In Prepaid Assets | $48,000 | $-62,000 | $912,000 | $110,000 |
| Change In Receivables | $-217,000 | $-228,000 | $255,000 | $746,000 |
| Changes In Account Receivables | $-217,000 | $-228,000 | $255,000 | $746,000 |
| Stock Based Compensation | $661,000 | $762,000 | $1,106,000 | $2,396,000 |
| Depreciation Amortization Depletion | $1,309,000 | $581,000 | $621,000 | $669,000 |
| Depreciation And Amortization | $1,309,000 | $581,000 | $621,000 | $669,000 |
| Net Income From Continuing Operations | $-21,230,000 | $-11,136,000 | $-13,583,000 | $-23,845,000 |
| Other Non Cash Items | - | $11,000 | $87,000 | - |
| Gain Loss On Investment Securities | - | $31,000 | $-3,041,000 | $711,000 |
| Preferred Stock Payments | - | - | - | $0 |
| Asset Impairment Charge | - | - | - | $0 |
| Income Tax Paid Supplemental Data | - | - | - | - |
Fetched: 2026-06-11